How GLP-1 Drugs Work

In 2005, the first GLP-1 receptor agonist received FDA approval for diabetes treatment. Few could have predicted that two decades later, these drugs would become one of the most prescribed medications globally, with celebrities discussing them on talk shows and shortages affecting patients worldwide. The GLP-1 revolution didn’t just change how we treat diabetes and obesity - it rewrote our understanding of metabolic health entirely.

The short answer

GLP-1 drugs work by mimicking a hormone that your gut naturally produces after eating. This hormone, called glucagon-like peptide-1, tells your pancreas to release more insulin while simultaneously telling it to stop releasing glucagon, the hormone that raises blood sugar. GLP-1 also slows down how quickly your stomach empties, making you feel fuller for longer, and it signals to your brain that you’re not hungry. The result is better blood sugar control and significant weight loss Nature.

The full picture

What is GLP-1 and where it comes from

GLP-1 stands for glucagon-like peptide-1, a hormone produced naturally in your body. Your intestines make GLP-1 in specialized cells called L-cells, which line the walls of your small intestine and colon. When you eat, especially when you consume carbohydrates and fats, these L-cells release GLP-1 into your bloodstream Cleveland Clinic.

The hormone belongs to a family of peptides that also includes glucagon, but GLP-1 has entirely different effects. What makes GLP-1 particularly interesting is that it only works when blood sugar is already elevated. This means it doesn’t cause dangerous drops in blood glucose the way some diabetes medications can. Your body breaks down GLP-1 within minutes, which is why scientists had to develop longer-lasting versions for therapeutic use.

How GLP-1 triggers insulin and suppresses glucagon

When GLP-1 binds to its receptor on pancreatic beta cells, it stimulates a cascade that causes those cells to release more insulin. This is called the incretin effect, and it’s something that people with type 2 diabetes often lose. But GLP-1 doesn’t work alone in managing blood sugar.

At the same time GLP-1 is boosting insulin release, it’s also suppressing glucagon secretion from pancreatic alpha cells. Glucagon is essentially the opposite of insulin - it tells your liver to release stored glucose when blood sugar gets too low. By calming glucagon production, GLP-1 drugs prevent your liver from dumping excess sugar into your bloodstream NCBI.

This dual action makes GLP-1 drugs particularly effective. You’re not just adding more insulin; you’re also reducing the hormone that’s working against it. The result is more stable blood glucose levels throughout the day, with fewer spikes after meals.

The gastric emptying effect and satiety

One of the most powerful effects of GLP-1 drugs is how they slow down gastric emptying. When your stomach empties more slowly, food sits in your digestive system longer, which means you feel full for extended periods after eating much smaller portions. This is called early satiety, and it’s a major driver of the weight loss these medications produce.

Beyond the physical effect in your stomach, GLP-1 also acts on your brain. The hormone crosses the blood-brain barrier and activates receptors in the hypothalamus, the part of your brain that controls hunger and satiety. This reduces food cravings and helps people make different choices about what and how much they eat UAB News.

Research from UAB researchers suggests that much of the benefit actually comes from these central nervous system effects. The drugs don’t just make your stomach feel full; they fundamentally change how your brain thinks about food.

Semaglutide, tirzepatide, and the different drugs

The GLP-1 drug landscape has expanded significantly. Semaglutide, sold as Ozempic and Wegovy, was one of the first widely adopted versions. It was followed by liraglutide (Victoza, Saxenda) and dulaglutide (Trulicity). These medications are injected weekly or daily and have become household names.

The newer generation includes tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss. Tirzepatide is different because it’s a dual agonist - it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action appears to produce even greater weight loss and blood sugar improvements Frontiers.

Research is now moving toward triple agonists that target GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide, currently in development, has shown promising results in clinical trials with even more dramatic weight loss outcomes.

The cardiovascular and other benefits

The benefits of GLP-1 drugs extend far beyond blood sugar and weight. Cardiovascular outcomes trials have shown significant reductions in major adverse cardiac events. Patients taking semaglutide, for example, have demonstrated lower rates of heart attack, stroke, and cardiovascular death Nature.

Scientists are exploring GLP-1 drugs for conditions ranging from non-alcoholic fatty liver disease to neurodegenerative disorders like Alzheimer’s and Parkinson’s. The anti-inflammatory effects of these medications appear to benefit multiple organ systems. Some research suggests potential benefits for kidney disease, addiction management, and even certain cancers.

Why it matters

The obesity epidemic represents one of the most significant public health challenges of our time. More than 650 million adults globally are classified as obese, a number that has nearly tripled since 1975. In the United States alone, the annual economic cost of obesity exceeds $1.7 trillion, including healthcare expenses and lost productivity.

GLP-1 drugs have demonstrated weight loss results that were previously impossible without surgery. Clinical trials show that semaglutide produces approximately 15% body weight loss, while tirzepatide has achieved up to 22.5% weight loss in some participants. These aren’t marginal improvements - they’re transformative outcomes that can reverse obesity-related conditions like type 2 diabetes, hypertension, and sleep apnea.

The implications extend to healthcare systems struggling with the downstream effects of metabolic disease. If a significant portion of the population can achieve sustained weight loss through medication, the reduction in diabetes complications, cardiovascular events, and joint replacements could reshape healthcare economics.

Common misconceptions

Myth 1: GLP-1 drugs are just expensive appetite suppressants

These medications do suppress appetite, but calling them mere appetite suppressants misses the fundamental biology at play. GLP-1 affects multiple hormonal pathways, improves insulin sensitivity, reduces inflammation, and changes how the body stores and uses fat. The weight loss occurs through coordinated metabolic changes, not simply making people feel hungry. Studies show that even when people eat less, they don’t experience the malnutrition or weakness that would accompany simple calorie restriction.

Myth 2: You’ll regain all the weight once you stop taking the medication

This is partially true but oversimplified. While many people do regain weight when stopping GLP-1 drugs, the amount regained is typically less than what they lost, and many maintain significant improvements. The more important point is that obesity is a chronic condition requiring ongoing management, much like hypertension or diabetes. Just as you wouldn’t tell a diabetic to stop taking insulin once their blood sugar normalizes, the expectation that someone should stop effective obesity treatment and somehow maintain results is unrealistic.

Key terms

GLP-1 (Glucagon-like peptide-1): A hormone produced in the intestines that regulates blood sugar and appetite by stimulating insulin release, suppressing glucagon, and promoting satiety.

Incretin effect: The phenomenon whereby gut hormones like GLP-1 enhance glucose-stimulated insulin secretion, accounting for the greater insulin response after oral glucose intake compared to intravenous glucose.

GIP (Glucose-dependent insulinotropic polypeptide): Another gut hormone that, like GLP-1, stimulates insulin secretion. Tirzepatide works on both GLP-1 and GIP receptors.

Beta cells: Pancreatic cells that produce and release insulin. GLP-1 drugs enhance the function of these cells.

Gastric emptying: The process by which food moves from the stomach to the small intestine. GLP-1 drugs slow this process, extending feelings of fullness.